Immunotherapy aiming at suppressing tumor development by relying on modifying or
strengthening the immune system prevails among cancer treatments and points out a new …

Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer
progression. This immune checkpoint molecule is selectively expressed in both tumor cells …

The immune checkpoint B7-H3 (CD276), a member of the B7 family with immunoregulatory
properties, has been identified recently as a novel target for immunotherapy for refractory …

Meningiomas are common tumors that account for approximately one third of CNS tumors
diagnosed every year. They are classified by the World Health Organization in grades I-III …

Background Craniopharyngioma (CP) is a common refractory tumor of the central nervous
system. However, little is known about the expression and clinical significance of B7 family …

Meningiomas, the most prevalent primary intracranial tumor (w35%), 1 arise from the
arachnoid cap cells in the meninges, the membranes that surround the brain and the spinal …

Background The combination of drug delivery with immune checkpoint targeting has been
extensively studied in cancer therapy. However, the clinical benefit for patients from this …

B7-H3 is a member of the B7 superfamily and a putative inhibitory immune checkpoint
molecule. Several early-phase clinical trials have reported promising anti-tumor activity and …

Meningioma is one of the most common primary tumors in the central nervous system
(CNS). A deeper understanding of its molecular characterization could provide potential …

For the developing field of gene therapy the successful address of the basic requirement
effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector …